Most humans would like to shed their fatty exteriors, but tuberculosis (TB)-causing bacteria rely on theirs for survival. Scientists at the University of Medicine and Dentistry of New Jersey (UMDNJ)-New Jersey Medical School have now discovered a drug that cripples the TB bug by dissolving its protective fatty coating, a finding that could eventually be used to improve TB treatment in humans. The study has been posted online by Nature Chemical Biology.
[More]
Among patients with suspected stage I/II pulmonary sarcoidosis who were undergoing confirmation of the condition via tissue sampling, the use of the procedure known as endosonographic nodal aspiration compared with bronchoscopic biopsy, the current diagnostic standard, resulted in greater diagnostic yield, according to a study in the June 19 issue of JAMA.
[More]
An international team led by scientists at The Scripps Research Institute (TSRI), the Howard Hughes Medical Institute and Albert Einstein College of Medicine of Yeshiva University has identified a highly promising new anti-tuberculosis compound that attacks the tuberculosis (TB) bacterium in two different ways.
[More]
An international team led by scientists at The Scripps Research Institute, the Howard Hughes Medical Institute and Albert Einstein College of Medicine of Yeshiva University has identified a highly promising new anti-tuberculosis compound that attacks the tuberculosis bacterium in two different ways.
[More]
Exciting progress has been made in the global fight against malaria. The malaria map continues to shrink each year; in the last ten years four countries have been certified malaria-free, and thirty-four additional countries are now working towards malaria elimination targets.
[More]
Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation (NASDAQ: CELG), today announced results from PALACE 3, the Company's third phase III study in psoriatic arthritis (PsA), at EULAR, the European Congress of Rheumatology annual meeting in Madrid, Spain.
[More]
Pyrazinamide (PZA)-a frontline tuberculosis drug-kills dormant persister bacteria and plays a critical role in shortening TB therapy. PZA is used for treating both drug susceptible and multi-drug resistant TB but resistance to PZA occurs frequently and can compromise treatment.
[More]
New data presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism show that apremilast administered to patients with psoriatic arthritis continues to demonstrate meaningful clinical responses beyond 24 weeks.
[More]
TORONTO, ON - Professor Frances Jamieson at the University of Toronto's Department of Laboratory Medicine and Pathobiology (LMP), and Medical Microbiologist, Public Health Ontario, is leading the way in tracking potentially deadly outbreaks of tuberculosis (TB) with a powerful new Geographic Information System (GIS) application, known as Ontario Universal Typing - Tuberculosis (OUT-TB) Web.
[More]
WHO estimates that up to half a million new cases of multidrug-resistant tuberculosis occur worldwide, each year. Current treatment regimens for MDR-TB present many challenges: treatment lasts 20 months or more, requiring daily administration of drugs that are more toxic, less effective, and far more expensive than those used to treat drug-susceptible TB.
[More]
A series of austerity reforms made by the Spanish government could lead to the effective dismantling of large parts of the country's healthcare system, with potentially detrimental effects on the health of the Spanish people, according to new research published in BMJ.
[More]
Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation, today announced 52-week results from PALACE 1, the Company's first phase III study in psoriatic arthritis at the European Congress of Rheumatology annual meeting in Madrid, Spain.
[More]
A team of Johns Hopkins researchers working with animals has developed a vaccine that prevents the virulent TB bacterium from invading the brain and causing the highly lethal condition TB meningitis, a disease that disproportionately occurs in TB-infected children and in adults with compromised immune system.
[More]
In India most people who are HIV positive don't know it, yet testing and treatment are relatively cheap and available. It would therefore meet international standards of cost-effectiveness - and save millions of lives for decades - to test every person in the billion-plus population every five years according to a new study published in the journal PLoS One.
[More]
Duke University, Durham, N.C., has been awarded $2 million to initiate a new clinical research network focused on antibacterial resistance. Total funding for the leadership group cooperative agreement award could reach up to $62 million through 2019.
[More]
A new approach may be able to reduce by more than half the time it takes health officials to identify Salmonella strains, according to researchers in Penn State's College of Agricultural Sciences.
[More]
[L]ast week, a divided court decided Arlington v. FCC, an important victory for Barack Obama's administration that will long define the relationship between federal agencies and federal courts. ... In a powerful and convincing opinion by Justice Antonin Scalia, the court's majority ruled that even when the agency is deciding on the scope of its own authority, it has the power to interpret ambiguities in the law.
[More]
Developing new vaccines to protect against diseases that plague humans is fraught with numerous challenges-one being that microbes tend to vary how they look on the surface to avoid being identified and destroyed by the immune system. However, researchers from Brigham and Women's Hospital (BWH) have discovered a sugar polymer that is common on the cell surface of several pathogens.
[More]
The Journal of the Pediatric Infectious Diseases Society today released its June issue, which includes a consensus statement of the global Sentinel Project on Pediatric Drug-Resistant Tuberculosis.
[More]
In a striking, unexpected discovery, researchers at Albert Einstein College of Medicine of Yeshiva University have determined that vitamin C kills drug-resistant tuberculosis bacteria in laboratory culture.
[More]